Connect with us

Janus Henderson Group plc Reports First Quarter 2019 Diluted EPS of US$0.48, or US$0.56 on an Adjusted Basis

Published

on

Reading Time: 13 minutes
  • Strong investment performance, with 69% and 74% of assets under
    management (“AUM”) outperforming relevant benchmarks on a 3 and 5 year
    basis, respectively, as at 31 March 2019
  • First quarter net income of US$94.1 million and adjusted net income of
    US$110.0 million
  • AUM of US$357.3 billion, up 9% compared to the prior quarter,
    reflecting positive markets partially offset by net outflows of US$7.4
    billion
  • Completed US$31 million of share buybacks during March; US$169 million
    remains authorised for buybacks in 2019
  • Board declared quarterly dividend of US$0.36 per share

LONDON–(BUSINESS WIRE)–Janus Henderson Group plc (NYSE/ASX: JHG; ‘JHG’, ‘the Group’) published
its first quarter 2019 results for the period ended 31 March 2019.

First quarter 2019 net income attributable to JHG was US$94.1 million
compared to US$106.8 million in the fourth quarter 2018 and US$165.2
million in the first quarter 2018. Adjusted net income attributable to
JHG, adjusted for one-time, acquisition and transaction related costs,
of US$110.0 million declined 6% compared to US$117.5 million in the
fourth quarter 2018 and declined 23% compared to US$143.6 million in the
first quarter 2018.

First quarter 2019 diluted earnings per share was US$0.48 compared to
US$0.54 in the fourth quarter 2018 and US$0.82 in the first quarter
2018. Adjusted diluted earnings per share of US$0.56 declined 5%
compared to US$0.59 in the fourth quarter 2018 and declined 21% versus
US$0.71 in the first quarter 2018.

Dick Weil, Chief Executive Officer of Janus Henderson Group plc,
stated:

“Overall investment performance for the quarter was strong, but we
continue to face pockets of underperformance which are driving
substantial net outflows. That said, we are seeing encouraging results
in several areas of our business, including momentum in the US retail
channel, primarily with our US Equity strategies, ongoing growth in our
Multi-Asset capability, and an improving environment in Continental
Europe.

Advertisement

“We finished the quarter with a 9% increase in assets under management
as strong investment performance and rebounding markets offset outflows.

“We continue to be financially disciplined, remaining focused on
investing in sustainable growth and upholding our commitment to return
cash flow to shareholders, with over US$100 million returned through
dividends and our share buyback programme in the first quarter.”

SUMMARY OF FINANCIAL RESULTS (unaudited) (in US$ millions,
except per share data or as noted)

The Group presents its financial results in US$ and in accordance with
accounting principles generally accepted in the United States of America
(‘US GAAP’ or ‘GAAP’). However, in the opinion of Management, the
profitability of the Group and its ongoing operations is best evaluated
using additional non-GAAP financial measures on an adjusted basis. See
adjusted statements of income reconciliation for additional information.

    Three months ended
31 Mar     31 Dec     31 Mar
  2019 2018 2018

GAAP basis:

Advertisement
Revenue 519.3 545.1 587.7
Operating expenses 394.8 395.1 411.5
Operating income 124.5 150.0 176.2
Operating margin 24.0% 27.5% 30.0%
Net income attributable to JHG 94.1 106.8 165.2
Diluted earnings per share 0.48 0.54 0.82
 
 
Three months ended
31 Mar 31 Dec 31 Mar
  2019 2018 2018

Adjusted basis:

Revenue 417.4 442.7 470.4
Operating expenses 274.0 277.4 281.6
Operating income 143.4 165.3 188.8
Operating margin 34.4% 37.3% 40.1%
Net income attributable to JHG 110.0 117.5 143.6
Diluted earnings per share 0.56 0.59 0.71
 

First quarter 2019 adjusted revenue of US$417.4 million decreased from
the fourth quarter 2018 result of US$442.7 million due to a slight
decline in management fee margin, given outflows in higher fee equity
products, and lower performance fees from segregated mandates. First
quarter 2019 adjusted operating income of US$143.4 million decreased
from US$165.3 million in the fourth quarter 2018, with lower adjusted
revenue slightly offset by lower operating expenses.

DIVIDEND AND SHARE BUYBACK

On 1 May 2019, the Board declared a first quarter dividend in respect of
the three months ended 31 March 2019 of US$0.36 per share. Shareholders
on the register on the record date of 13 May 2019 will be paid the
dividend on 29 May 2019. Janus Henderson does not offer a dividend
reinvestment plan.

As part of the US$200 million on-market buyback programme approved by
the Board in February, JHG purchased approximately 1.3 million of its
ordinary shares on the NYSE and its CHESS Depositary Interests (CDIs) on
the ASX in March, for a total outlay of US$31 million.

Advertisement

During the first quarter, the firm also purchased shares on market for
the annual share grants associated with 2018 variable compensation,
which is not connected with the buyback programme. As a firm policy,
Janus Henderson does not issue new shares to employees as part of its
annual compensation practices.

Net tangible assets per share

US$     31 Mar 2019     31 Dec 2018
Net tangible assets per ordinary share   1.31   1.32
 

Net tangible assets are defined by the ASX as being total assets less
intangible assets less total liabilities ranking ahead of, or equally
with, claims of ordinary shares.

AUM AND FLOWS (in US$ billions)

FX reflects movement in AUM resulting from changes in foreign currency
rates as non-USD denominated AUM is translated into USD. Redemptions
include impact of client switches. The reclassification in the fourth
quarter 2018 reflects an operational reclassification of an existing
client’s funds.

Advertisement
     

Total Group comparative AUM and flows

Three months ended
31 Mar       31 Dec       31 Mar
2019 2018 2018
Opening AUM 328.5 378.1 370.8
Sales 15.6 16.6 19.7
Redemptions (23.0 ) (25.0 ) (22.4 )
Net sales / (redemptions) (7.4 ) (8.4 ) (2.7 )
Market / FX 36.2   (41.2 ) 3.8  
Closing AUM 357.3 328.5 371.9
 
                                 

Quarterly AUM and flows by capability

Equities Fixed

Income

Quantitative
Advertisement

Equities

Multi-Asset Alternatives Total
AUM 31 Mar 2018 190.7 80.0 50.4 31.8 19.0 371.9
Sales 8.5 5.0 0.4 1.8 1.4 17.1
Redemptions (9.6 ) (5.6 ) (1.2 ) (1.3 ) (2.1 ) (19.8 )
Net sales / (redemptions) (1.1 ) (0.6 ) (0.8 ) 0.5 (0.7 ) (2.7 )
Market / FX 3.7   (2.9 ) 0.5   0.3   (0.7 ) 0.9  
AUM 30 Jun 2018 193.3 76.5 50.1 32.6 17.6 370.1
Sales 6.8 6.0 1.3 2.2 1.4 17.7
Redemptions (9.9 ) (7.6 ) (1.3 ) (1.3 ) (1.9 ) (22.0 )
Net sales / (redemptions) (3.1 ) (1.6 ) (0.0 ) 0.9 (0.5 ) (4.3 )
Market / FX 9.0   (0.4 ) 2.8   1.1   (0.2 ) 12.3  
AUM 30 Sep 2018 199.2 74.5 52.9 34.6 16.9 378.1
Sales 8.6 4.7 0.3 2.3 0.7 16.6
Redemptions (12.7 ) (6.0 ) (1.4 ) (2.0 ) (2.9 ) (25.0 )
Net sales / (redemptions) (4.1 ) (1.3 ) (1.1 ) 0.3 (2.2 ) (8.4 )
Market / FX (29.2 ) (1.3 ) (7.5 ) (2.5 ) (0.7 ) (41.2 )
Reclassification 1.7   0.5     (2.2 )    
AUM 31 Dec 2018 167.6 72.4 44.3 30.2 14.0 328.5
Sales 6.9 4.9 0.7 2.2 0.9 15.6
Redemptions (9.8 ) (7.7 ) (1.7 ) (1.5 ) (2.3 ) (23.0 )
Net sales / (redemptions) (2.9 ) (2.8 ) (1.0 ) 0.7 (1.4 ) (7.4 )
Market / FX 24.1   2.9   6.3   2.5   0.4   36.2  
AUM 31 Mar 2019 188.8 72.5 49.6 33.4 13.0 357.3
 
     

Average AUM

Three months ended
31 Mar

2019

      31 Dec
Advertisement

2018

      31 Mar

2018

Equities 182.8 179.5 194.6
Fixed Income 73.3 73.0 79.7
Quantitative Equities 48.3 47.6 51.4
Multi-Asset 32.1 32.2 32.1
Alternatives 13.5 15.5 19.6
Total 350.0 347.8 377.4
 

INVESTMENT PERFORMANCE

% of AUM outperforming benchmark (at 31 Mar 2019)

Advertisement
Capability       1 year       3 years       5 years
Equities 64% 69% 77%
Fixed Income 58% 92% 89%
Quantitative Equities 15% 14% 12%
Multi-Asset 88% 91% 91%
Alternatives 89% 98% 100%
Total 60% 69% 74%

Note: Outperformance is measured based on composite performance gross of
fees vs primary benchmark, except where a strategy has no benchmark
index or corresponding composite in which case the most relevant metric
is used: (1) composite gross of fees vs zero for absolute return
strategies, (2) fund net of fees vs primary index or (3) fund net of
fees vs Morningstar peer group average or median. Non-discretionary and
separately managed account assets are included with a corresponding
composite where applicable.

Cash management vehicles, ETFs, Managed CDOs, Private Equity funds and
custom non-discretionary accounts with no corresponding composite are
excluded from the analysis. Excluded assets represent 4% of AUM as at 31
Mar 2019. Capabilities defined by Janus Henderson.

% of mutual fund AUM in top 2 Morningstar quartiles (at 31 Mar 2019)

Capability       1 year       3 years       5 years
Equities 78% 72% 86%
Fixed Income 68% 42% 48%
Quantitative Equities 63% 3% 97%
Multi-Asset 84% 86% 88%
Alternatives 93% 33% 94%
Total 78% 67% 81%

Note: Includes Janus Investment Fund, Janus Aspen Series and Clayton
Street Trust (US Trusts), Janus Henderson Capital Funds (Dublin based),
Dublin and UK OEIC and Investment Trusts, Luxembourg SICAVs and
Australian Managed Investment Schemes. The top two Morningstar quartiles
represent funds in the top half of their category based on total return.
On an asset-weighted basis, 80% of total mutual fund AUM was in the top
2 Morningstar quartiles for the 10-year period ended 31 Mar 2019. For
the 1-, 3-, 5- and 10-year periods ending 31 Mar 2019, 62%, 50%, 62% and
62% of the 205, 195, 181 and 141 total mutual funds, respectively, were
in the top 2 Morningstar quartiles.

Analysis based on ‘primary’ share class (Class I Shares, Institutional
Shares or share class with longest history for US Trusts; Class A Shares
or share class with longest history for Dublin based; primary share
class as defined by Morningstar for other funds). Performance may vary
by share class. Rankings may be based, in part, on the performance of a
predecessor fund or share class and are calculated by Morningstar using
a methodology that differs from that used by Janus Henderson.
Methodology differences may have a material effect on the return and
therefore the ranking. When an expense waiver is in effect, it may have
a material effect on the total return, and therefore the ranking for the
period.

Advertisement

ETFs and funds not ranked by Morningstar are excluded from the analysis.
Capabilities defined by JHG. © 2019 Morningstar, Inc. All Rights
Reserved.

SECOND QUARTER 2019 RESULTS

Janus Henderson intends to publish its second quarter 2019 results on 31
July 2019.

FIRST QUARTER 2019 RESULTS BRIEFING INFORMATION

Chief Executive Officer Dick Weil and Chief Financial Officer Roger
Thompson will present these results on 2 May 2019 on a conference call
and webcast to be held at 8am EDT, 1pm BST, 10pm AEST.

Advertisement

Those wishing to participate should call:

United Kingdom       0800 358 6377 (toll free)
US & Canada 800 239 9838 (toll free)
Australia 1 800 573 793 (toll free)
All other countries: +1 323 794 2551 (this is not a toll free number)
Conference ID: 6246882
 

Access to the webcast and accompanying slides will be available via the
investor relations section of Janus Henderson’s website (www.janushenderson.com/IR).

About Janus Henderson

Janus Henderson Group (JHG) is a leading global active asset manager
dedicated to helping investors achieve long-term financial goals through
a broad range of investment solutions, including equities, fixed income,
quantitative equities, multi-asset and alternative asset class
strategies.

Janus Henderson has approximately US$357 billion in assets under
management (at 31 March 2019), more than 2,000 employees, and offices in
28 cities worldwide. Headquartered in London, the company is listed on
the New York Stock Exchange (NYSE) and the Australian Securities
Exchange (ASX).

Advertisement

FINANCIAL DISCLOSURES

Period ending 31 March 2018 reflects the reclassification of certain
revenue amounts from ‘Other revenue’ to ‘Shareowner servicing fees’.

     

Condensed consolidated statements of comprehensive income
(unaudited)

 
Three months ended
31 Mar       31 Dec       31 Mar
(in US$ millions, except per share data or as noted) 2019 2018 2018
Revenue:
Management fees 441.9 452.3 502.9
Performance fees (5.6 ) 3.5 (3.9 )
Shareowner servicing fees 35.9 37.0 38.4
Other revenue 47.1   52.3   50.3  
Total revenue 519.3   545.1   587.7  
 
Operating expenses:
Employee compensation and benefits 145.0 155.8 146.7
Long-term incentive plans 48.4 32.3 40.0
Distribution expenses 101.9 102.4 117.3
Investment administration 11.8 11.6 11.4
Marketing 7.5 12.8 8.5
General, administrative and occupancy 65.2 62.4 72.2
Depreciation and amortisation 15.0   17.8   15.4  
Total operating expenses 394.8   395.1   411.5  
 
Operating income 124.5 150.0 176.2
 
Interest expense (4.1 ) (4.0 ) (3.8 )
Investment gains (losses), net 13.3 (15.3 ) (0.7 )
Other non-operating income (expenses), net (3.9 ) 13.5   38.9  
Income before taxes 129.8 144.2 210.6
Income tax provision (29.9 ) (43.4 ) (47.4 )
Net income 99.9 100.8 163.2
Net loss (income) attributable to noncontrolling interests (5.8 ) 6.0   2.0  
Net income attributable to JHG 94.1 106.8 165.2
Less: allocation of earnings to participating stock-based awards (2.4 ) (2.8 ) (4.2 )
Net income attributable to JHG common shareholders 91.7   104.0   161.0  
 
Basic weighted-average shares outstanding (in millions) 191.8 193.3 195.9
Diluted weighted-average shares outstanding (in millions) 192.5 194.1 196.9
 
Diluted earnings per share (in US$) 0.48 0.54 0.82
 

Adjusted statements of income (unaudited)

The following are reconciliations of US GAAP basis revenues, operating
income, net income attributable to JHG and diluted earnings per share to
adjusted revenues, adjusted operating income, adjusted net income
attributable to JHG and adjusted diluted earnings per share.

Advertisement
      Three months ended
31 Mar       31 Dec       31 Mar
(in US$ millions, except per share data or as noted) 2019 2018 2018
Reconciliation of revenue to adjusted revenue
Revenue 519.3 545.1 587.7
Distribution expenses1 (101.9 ) (102.4 ) (117.3 )
Adjusted revenue 417.4   442.7   470.4  
 
Reconciliation of operating income to adjusted operating income
Operating income 124.5 150.0 176.2
Employee compensation and benefits2,4 4.3 4.4 2.9
Long-term incentive plans2 (0.2 ) (0.2 ) 0.1
Marketing2 0.1 0.1
General, administration and occupancy2,4 7.4 1.9 2.1
Depreciation and amortisation2,3 7.4   9.1   7.4  
Adjusted operating income 143.4   165.3   188.8  
 
Operating margin 24.0 % 27.5 % 30.0 %
Adjusted operating margin 34.4 % 37.3 % 40.1 %
 
Reconciliation of net income attributable to JHG to adjusted net
income attributable to JHG
Net income attributable to JHG 94.1 106.8 165.2
Employee compensation and benefits2,4 4.3 4.4 2.9
Long-term incentive plans2 (0.2 ) (0.2 ) 0.1
Marketing2 0.1 0.1
General, administration and occupancy2,4 7.4 1.9 2.1
Depreciation and amortisation2,3 7.4 9.1 7.4
Interest expense4 0.9 0.9 0.7
Other non-operating income (expenses), net4 0.4 0.3 (44.8 )
Income tax provision5 (4.3 ) (5.8 ) 9.9  
Adjusted net income attributable to JHG 110.0 117.5 143.6
Less: allocation of earnings to participating stock-based awards (2.8 ) (3.2 ) (3.6 )
Adjusted net income attributable to JHG common shareholders 107.2   114.3   140.0  
 
Weighted average diluted common shares outstanding – diluted (two
class) (in millions)
192.5 194.1 196.9
Diluted earnings per share (two class) (in US$) 0.48 0.54 0.82
Adjusted diluted earnings per share (two class) (in US$) 0.56 0.59 0.71
1   Distribution expenses are paid to financial intermediaries for the
distribution of JHG’s investment products. JHG management believes
that the deduction of third-party distribution, service and advisory
expenses from revenue in the computation of net revenue reflects the
nature of these expenses, as these costs are passed through to
external parties that perform functions on behalf of, and
distribute, the Group’s managed AUM.
2 Adjustments primarily represent integration costs in relation to the
Merger, including severance costs, legal costs and consulting fees.
JHG management believes these costs do not represent the ongoing
operations of the Group.
3 Investment management contracts have been identified as a separately
identifiable intangible asset arising on the acquisition of
subsidiaries and businesses. Such contracts are recognised at the
net present value of the expected future cash flows arising from the
contracts at the date of acquisition. For segregated mandate
contracts, the intangible asset is amortised on a straight-line
basis over the expected life of the contracts. JHG management
believes these non-cash and acquisition-related costs do not
represent the ongoing operations of the Group.
4 Adjustments for the three months ended 31 March 2019 and 31 December
2018 primarily represent increased debt expense as a consequence of
the fair value uplift on debt due to acquisition accounting and
deferred consideration costs associated with acquisitions prior to
the Merger. Adjustments for the three months ended 31 March 2018
include the gain on the sale of JHG’s back-office, middle-office and
custody function in the US to BNP Paribas, fair value movement on
options issued to Dai-ichi in addition to the same adjustments
affecting the three-month 2019 period. JHG management believes these
costs do not represent the ongoing operations of the Group.
5 The tax impact of the adjustments is calculated based on the US or
foreign statutory tax rate as they relate to each adjustment.
Certain adjustments are either not taxable or not tax-deductible.
 
           

Condensed consolidated balance sheets (unaudited)

 
31 Mar 31 Dec
(in US$ millions) 2019 2018
Assets
Cash and cash equivalents 717.1 880.4
Investment securities 270.7 291.8
Property, equipment and software, net 72.6 69.5
Intangible assets and goodwill, net 4,619.0 4,601.3
Assets of consolidated variable interest entities 330.0 323.9
Other assets 1,013.7 745.0
Total assets 7,023.1 6,911.9
 
Liabilities, redeemable noncontrolling interests and equity
Debt 318.4 319.1
Deferred tax liabilities, net 730.7 729.9
Liabilities of consolidated variable interest entities 11.0 6.5
Other liabilities 950.9 859.5
Redeemable noncontrolling interests 137.0 136.1
Total equity 4,875.1 4,860.8
Total liabilities, redeemable noncontrolling interests and equity 7,023.1 6,911.9
 
     

Condensed consolidated statements of cash flows (unaudited)

 
Three months ended
(in US$ millions) 31 Mar

2019

      31 Dec
Advertisement

2018

      31 Mar

2018

Cash provided by (used for)
Operating activities (34.7 ) 243.3 61.7
Investing activities 51.3 13.0 11.6
Financing activities (198.3 ) (127.8 ) (208.2 )
Effect of foreign exchange rate changes 5.0   (8.0 ) 6.1  
Net change during period (176.7 ) 120.5   (128.8 )
 

STATUTORY DISCLOSURES

Associates and joint ventures

Advertisement

At 31 March 2019, the Group holds interests in the following associates
and joint ventures managed through shareholder agreements with third
party investors, accounted for under the equity method:

  • Long Tail Alpha LLC. Ownership 20%

Basis of preparation

In the opinion of management of Janus Henderson Group plc, the condensed
consolidated financial statements contain all normal recurring
adjustments necessary to fairly present the financial position, results
of operations and cash flows of JHG in accordance with US GAAP. Such
financial statements have been prepared in accordance with the
instructions to Form 10-Q pursuant to the rules and regulations of the
SEC. Certain information and footnote disclosures normally included in
financial statements prepared in accordance with GAAP have been
condensed or omitted pursuant to such rules and regulations. The
financial statements should be read in conjunction with the annual
consolidated financial statements and notes presented in Janus Henderson
Group’s Annual Report on Form 10-K for the year ended 31 December 2018,
on file with the SEC (Commission file no. 001-38103). Events subsequent
to the balance sheet date have been evaluated for inclusion in the
financial statements through the issuance date and are included in the
notes to the condensed consolidated financial statements.

Corporate governance principles and recommendations

In the opinion of the Directors, the financial records of the Group have
been properly maintained, and the Condensed Consolidated Financial
Statements comply with the appropriate accounting standards and give a
true and fair view of the financial position and performance of the
Group. This opinion has been formed on the basis of a sound system of
risk management and internal control which is operating effectively.

FORWARD-LOOKING STATEMENTS DISCLAIMER

Advertisement

Past performance is no guarantee of future results. Investing involves
risk, including the possible loss of principal and fluctuation of value.

This document includes statements concerning potential future events
involving Janus Henderson Group plc that could differ materially from
the events that actually occur. The differences could be caused by a
number of factors including those factors identified in Janus Henderson
Group’s Annual Report on Form 10-K for the fiscal year ended 31 December
2018, on file with the Securities and Exchange Commission (Commission
file no. 001-38103), including those that appear under headings such as
‘Risk Factors’ and ‘Management’s Discussion and Analysis of Financial
Condition and Results of Operations’. Many of these factors are beyond
the control of JHG and its management. Any forward-looking statements
contained in this document are as at the date on which such statements
were made. Janus Henderson Group assumes no duty to update them, even if
experience, unexpected events, or future changes make it clear that any
projected results expressed or implied therein will not be realised.

Annualised, pro forma, projected and estimated numbers are used for
illustrative purposes only, are not forecasts and may not reflect actual
results.

The information, statements and opinions contained in this document do
not constitute a public offer under any applicable legislation or an
offer to sell or solicitation of any offer to buy any securities or
financial instruments or any advice or recommendation with respect to
such securities or other financial instruments.

Not all products or services are available in all jurisdictions.

Advertisement

Mutual funds in the US are distributed by Janus Henderson Distributors.

Please consider the charges, risks, expenses and investment
objectives carefully before investing. For a US fund prospectus or, if
available, a summary prospectus containing this and other information,
please contact your investment professional or call 800.668.0434. Read
it carefully before you invest or send money.

Janus Henderson, Janus, Henderson, Intech, Alphagen and Knowledge.
Shared are trademarks of Janus Henderson Group plc or one of its
subsidiaries. © Janus Henderson Group plc.

Contacts

Advertisement

Investor enquiries:
John Groneman
Global Head of
Investor Relations
+44 (0) 20 7818 2106
[email protected]

Jim
Kurtz
US Investor Relations Manager
+1 (303) 336 4529
[email protected]

Melanie
Horton
Non-US Investor Relations Manager
+44 (0) 20 7818 2905
[email protected]

Or

Investor
Relations
[email protected]

Advertisement

Media
enquiries:

North America:
Taylor Smith
+1 303
336 5031
[email protected]

EMEA:
Sally
Todd
+44 (0) 20 7818 2244
[email protected]

United
Kingdom: FTI Consulting

Tom Blackwell
+ 44 (0) 20 3727 1051
[email protected]

Asia
Pacific: Honner

Michael Mullane
+ 61 28248 3740
[email protected]

Advertisement

Germany

IMC Germany Announces Outstanding Preliminary Q3, 2024 Performance with 50% Growth Over Q2

Published

on

imc-germany-announces-outstanding-preliminary-q3,-2024-performance-with-50%-growth-over-q2

TORONTO and GLIL YAM, Israel, Oct. 2, 2024 /PRNewswire/ — IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the “Company“, “IMCannabis“, or “IMC“), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that the preliminary sales results in Germany by its German subsidiary, Adjupharm GmbH (“IMC Germany“), for the third quarter of 2024 have significantly exceeded expectations, showing a remarkable 50% increase in revenue compared to the second quarter, where IMC Germany sold about CAD$ 3.5M. This outstanding growth demonstrates IMC Germany’s successful execution of its strategic initiatives and strong market demand for its products.

Since the partial legalization of cannabis in Germany came into effect in April 2024, the demand for cannabis products in pharmacies has increased significantly, emphasizing the importance of a robust, reliable supply chain.

“Since April 1st, one of our key objectives was to ensure a supply chain strong enough to meet the increase in demand.  This preliminary 50% growth is testament, in part, to delivering on this objective,” said Oren Shuster, CEO of IMC. “We are thrilled with our Q3 performance, which not only surpassed our own targets but also highlights the dedication and hard work of our entire team.”  

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

Advertisement

The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and U.S. securities laws (collectively, “forward-looking statements”). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to statements relating to compliance with Nasdaq’s continued listing requirements, and timing and effect thereof; the potential outcome of the Licensing Agreement and the effect of collaboration with Carmel in the Israeli market and the potential exclusive launch of the BLKMKTTM brand this year in Germany.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include:  the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus Medical (collectively, the “Group”) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt and war, conflict and civil unrest in Eastern Europe and the Middle East.

Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Advertisement

CAUTIONARY NOTE REGARDING FUTURE ORIENTED FINANCIAL INFORMATION 

This press release may contain future oriented financial information (“FOFI”) within the meaning of Canadian securities legislation, about prospective results of operations, financial position or cash flows, based on assumptions about future economic conditions and courses of action, which FOFI is not presented in the format of a historical balance sheet, income statement or cash flow statement.

The FOFI has been prepared by management to provide an outlook of the Company’s activities and results and has been prepared based on a number of assumptions including the assumptions discussed under the heading above entitled “Cautionary Note Regarding Future Oriented Financial Information” and assumptions with respect to the costs and expenditures to be incurred by the Company, capital expenditures and operating costs, taxation rates for the Company and general and administrative expenses. Management does not have, or may not have had at the relevant date, firm commitments for all of the costs, expenditures, prices or other financial assumptions which may have been used to prepare the FOFI or assurance that such operating results will be achieved and, accordingly, the complete financial effects of all of those costs, expenditures, prices and operating results are not, or may not have been at the relevant date of the FOFI, objectively determinable. 

Importantly, the FOFI contained in this press release and the documents incorporated by reference herein, are, or may be, based upon certain additional assumptions that management believes to be reasonable based on the information currently available to management, including those assumptions discussed under the heading “Disclaimer for Forward-Looking Statements” and assumptions about: (i) the future pricing for the Company’s products, (ii) the future market demand and trends within the jurisdictions in which the Company may from time to time conduct the Company’s business, and (iii) the Company continued ability to maintain its capital to fund its ongoing business development and future growth.

The FOFI or financial outlook contained in this press release do not purport to present the Company’s financial condition in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, and there can be no assurance that the assumptions made in preparing the FOFI will prove accurate. The actual results of operations of the Company and the resulting financial results will likely vary from the amounts set forth in the analysis presented in any such document, and such variation may be material (including due to the occurrence of unforeseen events occurring subsequent to the preparation of the FOFI). The Company and management believe that the FOFI has been prepared on a reasonable basis, reflecting management’s best estimates and judgments as at the applicable date. However, because this information is highly subjective and subject to numerous risks including the risks discussed under the heading above entitled “Cautionary Note Regarding Future Oriented Financial Information”, FOFI or financial outlook within this in this press release should not be relied on as necessarily indicative of future results.

Advertisement

Company Contact:

Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]

Oren Shuster, CEO
IM Cannabis Corp.
[email protected]

Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/imc-germany-announces-outstanding-preliminary-q3-2024-performance-with-50-growth-over-q2-302265523.html

Advertisement
Continue Reading

Gedeon

Gedeon Richter presents analysis on cannabis usage among patients with schizophrenia: a new medical solution to a severe issue might be available

Published

on

gedeon-richter-presents-analysis-on-cannabis-usage-among-patients-with-schizophrenia:-a-new-medical-solution-to-a-severe-issue-might-be-available

A novel psychiatric scale developed by colleagues of Gedeon Richter Plc. in collaboration with academia was also presented at the 37th ECNP conference

BUDAPEST, Hungary, Sept. 25, 2024 /PRNewswire/ — During the 37th Annual Meeting of the European College of Neuropsychopharmacology (ECNP), held between 21-24 September 2024, new analyses of cariprazine studies were presented by Gedeon Richter Plc. First of all, cariprazine seems to be an effective treatment option for patients with schizophrenia and comorbid cannabis use disorder, according to one of the five posters presented at the congress. Furthermore, during an industry sponsored session, a new transdiagnostic scale for quantifying and visualizing symptom severity of patients with different psychiatric conditions was also presented, that was developed by the medical team of Gedeon Richter Plc. and recognized professors.

Schizophrenia often co-occurs with cannabis use disorder however, available antipsychotic treatments frequently fail to address both disorders. In a scientific poster showcased by Gedeon Richter at ECNP in Milan, cariprazine was presented to be a potentially effective treatment option for patients with first-episode schizophrenia and comorbid cannabis use disorder according to the results of a 6-month observational study. Four other scientific posters were also presented at the congress by Gedeon Richter about the role of cariprazine in the treatment of schizophrenia such as the efficacy of cariprazine in patients who develop akathisia as a side effect or the impact of functioning on the risk of relapse in patients treated with cariprazine vs placebo. Cariprazine is a 3rd generation antipsychotic medication with a unique receptor profile and proven efficacy in schizophrenia, including negative symptoms.

Lacking biomarkers in psychiatry calls for valid and reliable assessments of psychopathology across mental disorders that are easy to use, bridge research and clinical care, and that can capture clinician and patient perspectives. Recognizing this problem, the Gedeon Richter medical team together with experienced psychiatric professors developed a scale to handle this challenge. Using this new transdiagnostic scale called the Transdiagnostic Global Impression – Psychopathology (TGI-P) scale could help CNS professionals and psychologists to quickly assess and visualize symptoms in several psychiatric conditions. During an industry sponsored session, the details and the usability of the tool were shown to the audience.

About Richter  and About Cariprazine

Advertisement

 

 

View original content:https://www.prnewswire.co.uk/news-releases/gedeon-richter-presents-analysis-on-cannabis-usage-among-patients-with-schizophrenia-a-new-medical-solution-to-a-severe-issue-might-be-available-302258335.html

Continue Reading

Cannabis

Bioplastic Packaging Market Size Expected to Reach USD 87.98 Bn by 2033

Published

on

Ottawa, Sept. 20, 2024 (GLOBE NEWSWIRE) — The global bioplastic packaging market size was valued at USD 17.99 billion in 2023 and is predicted to increase from USD 21.09 billion in 2024 to USD 87.98 billion by 2033, a study published by Towards Packaging a sister firm of Precedence Statistics.

Key Takeaways: Leading Factors of the Bioplastic Packaging Market

  • Use of renewable resources due to growing sustainable demand is the major factor that drives the market.
  • Eco-friendly alternatives perceive growth in North America due to growing environmental concerns.
  • Food and beverage industry is the dominating sector in the market due to the increasing consumption of packed food.
  • Limited infrastructure for bioplastic processing is an unceasing challenge for the market.

Download Statistical Data: https://www.towardspackaging.com/download-statistics/5215

Bioplastic Packaging Market: At a Glance

The bioplastic packaging market revolves around adoption renewable packaging which can be used multiple times and which is an alternative to the fossil fuel-derived plastics. Along with this, resource depletion, reduction of carbon footprint and material waste are the leading objectives of the market. The demand for sustainable packaging solution and the increasing plastic waste has increased the demand of the market.

The bio-degradable feature attributes to the reusable function of bioplastic packaging. The consumer demand for sustainable packaging has also increased the demand of the bioplastic packaging, given the reason it provides resistance and prevents denting as well. The bioplastic material tends to degrade easily which also reduces landfill waste.

Regional Insights

Advertisement

Europe thrives with its vision of sustainable packaging demand

Europe is the dominating region in bioplastic packaging market. The sustainability focus of Europeans has sustained the environment and the alternative packaging solutions have increased the popularity of eco-friendly packaging. The European vision of preserving sustainability is also about turning packaging materials into recyclable or reusable material by 2030 and this has increased exploration of alternative materials, design strategies and mostly importantly waste management system.

Get the latest insights on packaging industry segmentation with our Annual Membership: https://www.towardspackaging.com/get-an-annual-membership

Europe targets to reduce unnecessary packaging by 10% in 2035 and by 15% in 2040. The demand for bioplastic as an alternative increase as Europe has strict regulations against plastic usage which aims to reduce the utilization of single use-plastic to prevent environmental hazards, especially, in marine environment and human health. In addition, European Union also aims at promoting circular economy and innovative sustainable packaging solutions with specific targets which are 77% separate collection target for plastic bottles by 2025 and will be increased to 90% by 2029. Furthermore, 25% of recycled plastic will be incorporated in PET beverage bottles from 2025 and will be increased by 30% in all plastic beverage bottles from 2030.

  • In January 2024, European retailers were relived to watch the inflation slow down as it had decreased the consumer rate by 0.1%. Despite the increasing rates and fleeting number of consumers, shopkeepers were committed to the sustainable drive. The UK consumer survey stated that 62% believed that high prices are pulling them back from being sustainable and 52% said that sustainable alternatives should have affordable prices.

North America is a steady region for the bioplastic packaging market due to its sustainable packaging demand which is also the growing consumer requirement. The impact of conventional plastic adds to the ocean litter hazard and as an alternative to reduce carbon print, sustainable solutions are being adopted. Although the American consumers worry more about convenience, price and quality given the increased purchasing rates and the tax-paying lifestyle, 40% of consumers pay more attention to the provided sustainable packaging.

The use of compostable packaging allows circular economy in the US and the companies are innovating new alternatives to support the sustainable drive and to increase their profit margin. According to U.S Environmental Protection Agency, reuse of plastic materials circulates the economy and reduces environmental impact if the material is in constant use instead of manufacturing new one. According to PEW’s research, reuse of plastics can accomplish 30% of reduction, substitution efforts by 17%, improved innovations in recycling by 20% and proper management at end-of-life can achieve a 23% reduction of plastic pollution in the environment.

Advertisement

If there’s anything you’d like to ask, feel free to get in touch with us @ [email protected]

  • In November 2023, Knox County, a startup had announced the of AgroRenew LLC and had also planned to build $83 million processing facility which was designed to convert food waste into eco-friendly bioplastics. The company had expected to establish itself in early 2024 and had aimed to produce 150,000 tons of bioplastic annually.

Asia-Pacific is the fastest growing region in bioplastic packaging market with its large population as a contributor and its rapidly increasing industrial sector. The packed food consumption and the boom of e-commerce also gave preference to sustainable packaging due to strict regulations and subsidies provided to promote the compostable packaging. According to Department of Biotechnology, Ministry of Science & Technology, Government of India, the usage of single-use plastic (SUPs) was intended to stop by December 2022. The policy of Government of India (GOI) was changed to promote the development of biodegradable plastic products instead of single-use plastic.

The method used for testing substances should be able to demonstrate biodegradability as per national and international standards and should also be interim approved and receive provisional certification of biodegradability. China having a large industrial production had signed the Paris agreement to reduce carbon footprint and oil dependency as well.

Although the National Development and Reform Commission and Ministry of Ecology and Environment had plans to reduce plastic garbage, the limited infrastructure for recycling and manufacturing biodegradable plastic came as a challenge. The Chinese Government had implemented ban on plastic recycled and prohibition of non-biodegradable single-use plastic.

  • In February 2024, Balrampur Chini Mills Limited (BCML), which is a leading integrated sugar mill Kolkata-based company had announced a project with integration of ₹2,000 crore and it was going be the first industrial bioplastic plant in India. The company also stated that it had well-aligned sustainable goals to combat the climate change.  

Driver

Government regulations drive the bioplastic packaging market

The major driving factor is the environmental regulations due to increasing plastic waste production which is a problem for the eco-system. The growing concern for climate change, increasing plastic pollution and landfill waste has led to the utilization of bioplastic packaging which is reliable and bio-degradable. The government policies promote the use of biodegradable and bioplastic packaging as it reduces the use of plastic and also its generation.

Advertisement

The government initiatives will increase sales, improve brand perception and also contribute to cost-savings. According to the Consumer Brands Association, FMCG manufacturers have adopted 100% recycled packaging by 2030. 

Restraint

Limited infrastructure and higher costs of materials hinder the market growth

The leading challenges which hinder the growth of bioplastic packaging market is high material costs and limited infrastructure. The manufacturing process and raw materials can affect the production of biodegradable packaging. The limited infrastructure also poses as a challenge for the manufacturing and recycling processes.

Opportunity

Advertisement

Integration of Artificial Intelligence

The technological advancement offers new trends which are development of raw materials like algae, mushroom mycelium, and agricultural waste which poses as an emerging alternative. The major factor which technology can contribute is in biodegradability which will enhance the decomposing process of plastic and it also offers upcoming features like the antimicrobial properties which are significant for medical applications, use of UV resistance for outdoor use, and improved barrier properties for food packaging. Collaboration among leading industries can create more innovate and ground-breaking effective solutions for the bioplastic packaging market.

Top Companies Leading the Bioplastic Packaging Market

  • Amcor plc
  • Novamont S.p.A
  • NatureWorks, LLC
  • Coveris
  • Sealed Air
  • Alpha Packaging
  • Constantia Flexibles Group GmbH
  • Mondi plc
  • Truegreen
  • Transcontinental Inc.
  • ALPLA
  • Envigreen
  • Nature’s Bio Plastic
  • Raepak Ltd.
  • Tipa-corp Ltd.
  • Treemera GmbH
  • Element Packaging Ltd
  • Alpagro Packaging

Recent Development

Company  Balrampur Sugar Mills Firm
Headquarters Uttar Pradesh, India
Recent Development In June 2024, the Uttar Pradesh Government had announced to build a bioplastic park in the Lakhimpur Kheri district which aimed at increasing local economy. The bioplastic park was designed to promotes the usage of bioplastic plastics.
Company Praj Industries
Headquarters Maharashtra
Recent Development In February 2024, Praj Industries had announced that its pilot plant for polylactic acid (PLA) will be completed by April 2024. The company will develop renewable chemicals which is a part of R&D push. The Union Budget had also contemplated a policy for bio-manufacturing and bio foundry.

Segmental Insights

By Type

Advertisement

The flexible segment is the dominating segment in the bioplastic packaging market. It is dominating due to its properties which are conserving resources and contributing to the sustainability. The flexible segment provides convenience, strong protection and reduces wastage of food and can also resist denting and breakage. Apart from this, it also increases shelf life of the products and the packaging is in demand due to its features like multi-layer construction and eco-friendly packaging solution. Lightness, safety and resistance are the factors which increase the demand of bioplastic packaging.

The rigid segment is the fastest growing segment in the bioplastic packaging market. It will dominate the market due to its properties which are providing protection, resistance and preserving product quality. The rigid segment offers a durable and reliable packaging which makes it preferred among the consumers. Customization and exceptional product protection are the essential features of the rigid segment.

By Application Type

The food and beverage segment are the dominating segment in the bioplastic packaging market. The segment dominates due extended shelf life provided to the food products and long-lasting convenience and visibility. The bioplastic packaging depends upon the type of packaging it provides which provides string barrier against external elements like oxygen, moisture and prevents food spoilage as well. Th global consumption of containers like boxes, bags, jars and pouches has increased the bioplastic packaging demand in food sector.

The consumer and goods segment are the fastest growing segment in the bioplastic films packaging market. The segment dominates due to sealed packaging and robust protection by bioplastic packaging.

Advertisement

More Insights of Towards Packaging

  • The global end-of-line packaging market size is estimated to reach USD 9.50 billion by 2033, up from USD 6.14 billion in 2023, at a compound annual growth rate (CAGR) of 4.60% from 2024 to 2033.
  • The global surgical instruments packaging market size reached US$ 24.8 billion in 2023 and is projected to hit around US$ 49.1 billion by 2034, expanding at a CAGR of 6.55% during the forecast period from 2024 to 2033.
  • The global cannabis packaging market size reached USD 2.32 billion in 2023 and is projected to hit around USD 22.10 billion by 2034, expanding at a CAGR of 22.74% during the forecast period from 2024 to 2034.
  • The global clinical trial packaging market size reached USD 2.95 billion in 2023 and is projected to hit around USD 9.12 billion by 2034, expanding at a CAGR of 10.80% during the forecast period from 2024 to 2033.
  • The global panel level packaging market size is estimated to reach USD 11.13 billion by 2033, up from USD 0.43 billion in 2023, at a compound annual growth rate (CAGR) of 38.60% from 2024 to 2033.
  • The global hazardous goods packaging market size reached US$ 11.50 billion in 2023 and is projected to hit around US$ 21.38 billion by 2034, expanding at a CAGR of 5.80% during the forecast period from 2024 to 2033.
  • The global rigid tray market size reached US$ 11.65 billion in 2024 and is projected to hit around US$ 14.72 billion by 2034, expanding at a CAGR of 2.37% during the forecast period from 2024 to 2034.
  • The global cider packaging market size is estimated to reach USD 7.05 billion by 2033, up from USD 4.08 billion in 2023, at a compound annual growth rate (CAGR) of 5.77% from 2024 to 2033.
  • The global boxboard packaging market size is estimated to reach USD 117.61 billion by 2033, up from USD 65.73 billion in 2023, at a compound annual growth rate (CAGR) of 6.12% from 2024 to 2033.
  • The global corrugated plastic tray market size reached US$ 665.47 million in 2023 and is projected to hit around US$ 1190.73 million by 2034, expanding at a CAGR of 5.14% during the forecast period from 2024 to 2034.

Bioplastic Packaging Market Segment

By Material

  • Biodegradable
    • Polylactic Acid
    • Starch Blends
    • Polybutylene Adipate Terephthalate (PBAT)
    • Polybutylene Succinate (PBS)
    • Others
  • Non-biodegradable
    • Bio Polyethylene
    • Bio Polyethylene Terephthalate
    • Bio Polyamide
    • Others

By Type

  • Flexible
  • Rigid

By Application 

  • Food & Beverages
  • Consumer Goods
  • Cosmetic & Personal Care
  • Pharmaceuticals
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait

View Bioplastic Packaging Market Full TOC: https://www.towardspackaging.com/table-of-content/bioplastic-packaging-market-sizing

Buy Premium Global Insight @ https://www.towardspackaging.com/price/5215

If you have any questions, please feel free to contact us at [email protected]

About Us

Advertisement

Towards Packaging is a leading global consulting firm specializing in providing comprehensive and strategic research solutions. With a highly skilled and experienced consultant team, we offer a wide range of services designed to empower businesses with valuable insights and actionable recommendations. We stay abreast of the latest industry trends and emerging markets to provide our clients with an unrivalled understanding of their respective sectors. We adhere to rigorous research methodologies, combining primary and secondary research to ensure accuracy and reliability. Our data-driven approach and advanced analytics enable us to unearth actionable insights and make informed recommendations. We are committed to delivering excellence in all our endeavours. Our dedication to quality and continuous improvement has earned us the trust and loyalty of clients worldwide.

Browse our Brand-New Journal:

https://www.towardshealthcare.com/

https://www.towardsautomotive.com/

https://www.precedenceresearch.com/

Advertisement

For Latest Update Follow Us: https://www.linkedin.com/company/towards-packaging/

Get Our Freshly Printed Chronicle: https://www.packagingwebwire.com/

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania